Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules

British Journal of Cancer

Volumn 103, Issue 6, 2010, Pages 802-811

  Korner A ^a   Mudduluru, G ^a   Manegold, C ^a   Allgayer, H ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

enzastaurin; FHIT; invasion and metastasis; RASSF1; u PAR

Indexed keywords

ENZASTAURIN; MATRIGEL; SMALL INTERFERING RNA; UROKINASE RECEPTOR; INDOLE DERIVATIVE;

ARTICLE; CANCER GENETICS; CANCER INVASION; CHORIOALLANTOIS; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; METASTASIS; METASTASIS INHIBITION; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; CELL PROLIFERATION; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; GENE SILENCING; LUNG TUMOR; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NON SMALL CELL LUNG CANCER; NUCLEIC ACID HYBRIDIZATION; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE KNOCKDOWN TECHNIQUES; HUMANS; INDOLES; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NUCLEIC ACID HYBRIDIZATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77956435904     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605818     Document Type: Article

References (62)

1. Ali S, Al-Sukhun S, El-Rayes BF, Sarkar FH, Heilbrun LK, Philip PA (2009) Protein kinases C isozymes are differentially expressed in human breast carcinomas. Life Sci 84: 766-771
2. Allgayer H, Wang H, Gallick GE, Crabtree A, Mazar A, Jones T, Kraker AJ, Boyd DD (1999) Transcriptional induction of the urokinase receptor gene by a constitutively active Src. Requirement of an upstream motif (-152/-135) bound with Sp1. J Biol Chem 274: 18428-18437
3. Balendran A, Hare GR, Kieloch A, Williams MR, Alessi DR (2000) Further evidence that 3-phosphoinositidedependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms. FEBS Lett 484: 217-223
4. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S, Taylor IM, Iannettoni MD, Orringer MB, Hanash S (2002) Gene-expression profiles predict survival of patients with lung adeno-carcinoma. Nat Med 8: 816-824
5. Beyer BC, Heiss MM, Simon EH, Gruetzner KU, Babic R, Jauch KW, Schildberg FW, Allgayer H (2006) Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens. Cancer 106: 1026-1035
6. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, Loda M, Weber G, Mark EJ, Lander ES, Wong W, Johnson BE, Golub TR, Sugarbaker DJ, Meyerson M (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98: 13790-13795
7. Borczuk AC, Gorenstein L, Walter KL, Assaad AA, Wang L, Powell CA (2003) Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol 163: 1949-1960
8. Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS (2006) Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 24: 4092-4099
9. Casey EM, Harb W, Bradford D, Bufill J, Nattam S, Patel J, Fisher W, Latz JE, Wu J, Hanna N (2009) Randomized, double blind, multicenter, phase II study of pemetrexed (PEM), carboplatin (CARBO), bevacizumab (BEV) with enzastaurin (ENZ) or placebo (PBO) in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer (NSCLC) (Abstract no. 8035). J Clin Oncol 27: 15s
10. Chen JJ, Peck K, Hong TM, Yang SC, Sher YP, Shih JY, Wu R, Cheng JL, Roffler SR, Wu CW, Yang PC (2001) Global analysis of gene expression in invasion by a lung cancer model. Cancer Res 61: 5223-5230
11. Clark AS, West KA, Blumberg PM, Dennis PA (2003) Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. Cancer Res 63: 780-786
12. da Rocha AB, Mans DR, Regner A, Schwartsmann G (2002) Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? Oncologist 7: 17-33
13. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP (2000) Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25: 315-319
14. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH (2008) Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 34: 22-36
15. Diederichs S, Bulk E, Steffen B, Ji P, Tickenbrock L, Lang K, Zänker KS, Metzger R, Schneider PM, Gerke V, Thomas M, Berdel WE, Serve H, Müller-Tidow C (2004) S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res 64: 5564-5569
16. Douglas H, Robert AW (2000) The hallmarks of cancer. Cell 100: 57-70
17. Eberwine J, Spencer C, Miyashiro K, Mackler S, Finnell R (1992) Complementary DNA synthesis in situ: methods and applications. Methods Enzymol 216: 80-100
18. Fang X, Yu S, Tanyi JL, Lu Y, Woodgett JR, Mills GB (2002) Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 22: 2099-2110
19. Faoro L, Cervantes GM, Ferguson BD, Seiwert TY, Yala S, Vigneswaran WT, Westerhoff M, Tretiakova MS, Ferguson MK, Moura GL, Husain AN, Vokes EE, Salgia R (2009) MET/PKCss expression correlate with metastasis and inhibition is synergistic in lung cancer. J Carcinog 8: 15
20. Faul MM, Gillig JR, Jirousek MR, Ballas LM, Schotten T, Kahl A, Mohr M (2003) Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. Bioorg Med Chem Lett 13: 1857-1859
21. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604-4613
22. Gemma A, Takenaka K, Hosoya Y, Matuda K, Seike M, Kurimoto F, Ono Y, Uematsu K, Takeda Y, Hibino S, Yoshimura A, Shibuya M, Kudoh S (2001) Altered expression of several genes in highly metastatic subpopulations of a human pulmonary adenocarcinoma cell line. Eur J Cancer 37: 1554-1561
23. Giovannetti E, Honeywell R, Hanauske AR, Tekle C, Kuenen B, Sigmond J, Giaccone G, Peters GJ (2010) Pharmacological aspects of the enzastaurin- pemetrexed combination in non-small cell lung cancer (NSCLC). Curr Drug Targets 11: 12-28
24. Goekjian PG, Jirousek MR (2001) Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs 10: 2117-2140
25. Gokmen-Polar Y, Murray NR, Velasco MA, Gatalica Z, Fields AP (2001) Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis. Cancer Res 61: 1375-1381
26. Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, Banks C, Capen A, Goode R, Lewis JE, Sams L, Huss KL, Campbell RM, Iversen PW, Neubauer BL, Brown TJ, Musib L, Geeganage S, Thornton D (2005) The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65: 7462-7469
27. Gridelli C, Langer C, Maione P, Rossi A, Schild SE (2007) Lung cancer in the elderly. J Clin Oncol 25: 1898-1907
28. Guo K, Li Y, Kang X, Sun L, Cui J, Gao D, Liu Y (2009) Role of PKCbeta in hepatocellular carcinoma cells migration and invasion in vitro: a potential therapeutic target. Clin Exp Metastasis 26: 189-195
29. Hanauske AR, Lahn M, Musib LC, Weigang-Köhler K, Yilmaz E, Graefe T, Kuenen B, Thornton D, McNealy P, Giaccone G (2009) Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. Ann Onco 20: 1565-1575
30. Hayes DN, Monti S, Parmigiani G, Gilks CB, Naoki K, Bhattacharjee A, Socinski MA, Perou C, Meyerson M (2006) Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol 24: 5079-5090
31. Heighway J, Knapp T, Boyce L, Brennand S, Field JK, Betticher DC, Ratschiller D, Gugger M, Donovan M, Lasek A, Rickert P (2002) Expression profiling of primary non-small cell lung cancer for target identification. Oncogene 21: 7749-7763
32. Hellmann GM, Fields WR, Doolittle DJ (2001) Gene expression profiling of cultured human bronchial epithelial and lung carcinoma cells. Toxicol Sci 61: 154-163
33. Henic E, Borgfeldt C, Christensen IJ, Casslén B, Høyer-Hansen G (2008) Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res 14: 5785-5793
34. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics. CA Cancer J Clin 55: 10-30
35. Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA (1999) Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene over-expression. Cancer Res 59: 3333-3339
36. Jo M, Thomas KS, O'Donnell M, Gonias SL (2003) Epidermal growth factor receptor-dependent and-independent cell-signaling pathways originating from the urokinase receptor. J Biol Chem 278: 1642-1646
37. Karhausen J, Kong T, Narravula S, Colgan SP (2005) Induction of the von Hippel-Lindau tumor suppressor gene by late hypoxia limits HIF-1 expression. J Cell Biochem 95: 1264-1275
38. Keyes K, Cox K, Treadway P, Mann L, Shih C, Faul MM, Teicher BA (2002) An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy. Cancer Res 62: 5597-5602
39. Kreisl TN, Kotliarova S, Butman JA, Albert PS, Kim L, Musib L, Thornton D, Fine HA (2010) A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro Oncol 12: 181-189
40. Laufs S, Schumacher J, Allgayer H (2006) Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle 5: 1760-1771
41. Lee KW, Kim SG, Kim HP, Kwon E, You J, Choi HJ, Park JH, Kang BC, Im SA, Kim TY, Kim WH, Bang YJ (2008) Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res 68: 1916-1926
42. Leupold JH, Asangani I, Maurer GD, Lengyel E, Post S, Allgayer H (2007) Src induces urokinase receptor gene expression and invasion/intravasa-tion via activator protein-1/p-c-Jun in colorectal cancer. Mol Cancer Res 5: 485-496
43. Marchetti A, Tinari N, Buttitta F, Chella A, Angeletti CA, Sacco R, Mucilli F, Ullrich A, Iacobelli S (2002) Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res 62: 2535-2539
44. Morgillo F, Martinelli E, Troiani T, Laus G, Pepe S, Gridelli C, Ciardiello F (2008) Sequence-dependent, synergistic antiproliferative and proapop-totic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells. Mol Cancer Ther 7: 1698-1707
45. Mudduluru G, Allgayer H (2008) The human receptor tyrosine kinase Axl gene-promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation. Biosci Rep 28: 161-176
46. Müller-Tidow C, Metzger R, Kügler K, Diederichs S, Idos G, Thomas M, Dockhorn-Dworniczak B, Schneider PM, Koeffler HP, Berdel WE, Serve H (2001) Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage nonsmall cell lung cancer. Cancer Res 61: 647-653
47. Nikolova DA, Asangani IA, Nelson LD, Hughes DP, Siwak DR, Mills GB, Harms A, Buchholz E, Pilz LR, Manegold C, Allgayer H (2009) Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity. Cancer Res 69: 2461-2470
48. Phillips RJ, Mestas J, Gharaee-Kermani M, Burdick MD, Sica A, Belperio JA, Keane MP, Strieter RM (2005) Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 280: 22473-22481
49. Querfeld C, Rizvi MA, Kuzel TM, Guitart J, Rademaker A, Sabharwal SS, Krett NL, Rosen ST (2006) The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 126: 1641-1647
50. Richards DA, Kuefler PR, Becerra C, Wilfong LS, Gersh RH, Boehm KA, Zhan F, Asmar L, Myrand SP, Hozak RR, Zhao L, Gill JF, Mullaney BP, Obasaju CK, Nicol SJ (2009) Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a Phase II, randomized, noncomparative study. Invest New Drugs [Epub ahead of print]
51. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Mesirov J, Neuberg DS, Lander ES, Aster JC, Golub TR (2002) Diffuse large B cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8: 68-74
52. Skurk C, Maatz H, Rocnik E, Bialik A, Force T, Walsh K (2005) Glycogen-synthase kinase3beta/beta-catenin axis promotes angiogenesis through activation of vascular endothelial growth factor signaling in endothelial cells. Circ Res 96: 308-318
53. Tekle C, Giovannetti E, Sigmond J, Graff JR, Smid K, Peters GJ (2008) Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. Br J Cancer 99: 750-759
54. Tsai PW, Shiah SG, Lin MT, Wu CW, Kuo ML (2003) Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathway. J Biol Chem 278: 5750-5759
55. Wang J, Zhao W, Guo Y, Zhang B, Xie Q, Xiang D, Gao J, Wang B, Chen Z (2009) The expression of RNA-binding protein HuR in non-small cell lung cancer correlates with vascular endothelial growth factor-C expression and lymph node metastasis. Oncology 76: 420-429
56. Watkins V, Hong S, Lin B (2006) Enzastaurin safety review: data from phase I and phase II trials. J Clin Oncol 24: 608
57. Werle B, Kotzsch M, Lah TT, Kos J, Gabrijelcic-Geiger D, Spiess E, Schirren J, Ebert W, Fiehn W, Luther T, Magdolen V, Schmitt M, Harbeck N (2004) Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator- receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. Anticancer Res 24: 4147-4161
58. Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE, Fine HA (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28: 1168-1174
59. Wikman H, Kettunen E, Seppänen JK, Karjalainen A, Hollmén J, Anttila S, Knuutila S (2002) Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene 21: 5804-5813
60. Willey CD, Xiao D, Tu T, Woon Kim K, Moretti L, Niermann KJ, Tawtawy MN, Quarles CC, Lu B (2009) Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation. Int J Radiat Oncol Biol Phys 20: 1565-1575
61. Zhang Q, Tang X, Zhang ZF, Velikina R, Shi S, Le AD (2007) Nicotine induces hypoxia-inducible factor-1alpha expression in human lung cancer cells via nicotinic acetylcholine receptor-mediated signaling pathways. Clin Cancer Res 13: 4686-4694
62. Zochbauer-Muller S, Gazdar AF, Minna JD (2002) Molecular pathogenesis of lung cancer. Annu Rev Physiol 64: 681-708